Exelixis
EXEL
$21.02
Share price
-0.45%
Change (1 day)
7.82%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total assets
Total assets on the balance sheet as of March 2024 : $2.80 B
According to Exelixis's latest financial reports the company's total assets are $2.80 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Exelixis - Total assets on balance sheet (from 2001 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-12-31 | $2.94 B | -4.2% |
| 2022-12-31 | $3.07 B | 17.4% |
| 2021-12-31 | $2.61 B | 22.41% |
| 2020-12-31 | $2.13 B | 13.35% |
| 2019-12-31 | $1.88 B | 32.58% |
| 2018-12-31 | $1.42 B | 117.05% |
| 2017-12-31 | $0.65 B | 10% |
| 2016-12-31 | $0.59 B | 79.25% |
| 2015-12-31 | $0.33 B | 2.81% |
| 2014-12-31 | $0.32 B | -35.77% |
| 2013-12-31 | $0.50 B | -30.21% |
| 2012-12-31 | $0.72 B | 83.36% |
| 2011-12-31 | $0.39 B | 9% |
| 2010-12-31 | $0.36 B | 5.06% |
| 2009-12-31 | $0.34 B | -14.49% |
| 2008-12-31 | $0.40 B | -2.55% |
| 2007-12-31 | $0.41 B | 4.22% |
| 2006-12-31 | $0.39 B | 18.85% |
| 2005-12-31 | $0.33 B | 14.2% |
| 2004-12-31 | $0.29 B | -18.57% |
| 2003-12-31 | $0.35 B | 5.51% |
| 2002-12-31 | $0.33 B | -2.16% |
| 2001-12-31 | $0.34 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $171.96 B | 6,033.43% | 🇺🇸 USA |
 Pfizer PFE | $226.50 B | 7,978.50% | 🇺🇸 USA |
 Amgen AMGN | $97.15 B | 3,365.14% | 🇺🇸 USA |
 Sanofi SNY | $139.81 B | 4,886.75% | 🇫🇷 France |
 Merck MRK | $106.67 B | 3,704.73% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $99.03 B | 3,432.09% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $73.94 B | 2,537.25% | 🇬🇧 UK |
 Curis CRIS | $77.28 M | -97.24% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $0.10 B | -96.39% | 🇺🇸 USA |